Purple Biotech Ltd.
PPBT | NASDAQ
$1.13
+$0.04 (+3.67%)
At close: Oct 30, 2026, 3:59 PM ET
$1.17
+$0.04 (+3.54%)
Pre-market:
Nov 2, 2026, 9:14 AM ET
+3.67%
(1D)No price chart data available for 1D timeframe.
Rating
34.5
+3.5 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #672/1028 (Top 65%)
Key Statistics
Market Data
Market Cap $156.04K
1D Range
1.10 1.15
52W Range
0.92 8.74
Valuation (TTM)
PE -0.51
PB 0.01
EV/EBITDA 0.24
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $17.00
Cash Flow
FCF Yield -4974.5%
SBC Adj. FCF Yield -5177.7%
SBC Impact -4.1%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 98.5% |
50.1%
FCF 3Y | 5Y 43.5% |
19.1%
Returns
ROA -172.9%
ROE -151.8%
ROIC -241.9%
Financial Health
Net Cash
$6.11M
Current Ratio 3.72
Interest Coverage -116.29
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor im...
Sector Healthcare
Industry Biotechnology
Employees 10
IPO Date Nov 20, 2015
Website purple-biotech.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$17.00
Upside
+1404.42%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PPBT